RCE
vs
S
S&P/ASX 300
RCE
Over the past 12 months, RCE has outperformed S&P/ASX 300, delivering a return of +27% compared to the S&P/ASX 300's +11% growth.
Stocks Performance
RCE vs S&P/ASX 300
Performance Gap
RCE vs S&P/ASX 300
Performance By Year
RCE vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Recce Pharmaceuticals Ltd
Glance View
Recce Pharmaceuticals Ltd. is engaged in the research and development of pharmaceutical drugs that kill germs. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-01-15. The firm is engaged in development and commercialization of synthetic anti-Infectives designed to address antibiotic resistant superbugs and emerging viral pathogens. The firm pipeline consist of RECCE 327, RECCE 435, and RECCE 529 for viral infections with action against hyper-mutation on bacteria and viruses. Its patent candidate RECCE 327 is an intravenous therapy, which is developed for treatment of serious and potentially life-threatening infections including sepsis due to Gram-positive and Gram-negative bacteria, including their superbug forms. Its RECCE 435 is a broad-spectrum synthetic polymer antibiotic formulated for oral use. Its RECCE 529 is a synthetic polymer anti-infective, which is focused on viral indications. The Company’s RECCE technologies are targeting synergistic unmet medical needs.
